Compare iShares MSCI Japan ETF (EWJ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Pfizer Inc — how do they compare? iShares MSCI Japan ETF trades at $97.45 (market cap $23.87B), while Pfizer Inc trades at $27.95 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 6.6× iShares MSCI Japan ETF's market cap, and Pfizer Inc pays a 6.18% dividend while iShares MSCI Japan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and Pfizer Inc for 158 Days on average.
| EWJ | PFE | |
|---|---|---|
Market Cap | $23.87B | $158.56B |
Volume | 5,412,820 | 44,138,282 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $29.02 |
52-Week Low | $78.36 | $23.67 |
Typical Hold Time | 56 Days | 158 Days |
Enterprise Value | — | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $98.32, down 1.01% on the day amid broader Asian market pressures. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. Recent news highlights Japan's monetary policy shifts with BOJ rate hikes and yen volatility creating both opportunities and challenges for Japanese equities. The ETF has demonstrated strong performance in 2026, outperforming the S&P 500 with gains exceeding 20% according to Zacks Investment Research (September 30, 2026).
The outlook for EWJ remains constructive given Japan's economic reforms and AI sector growth, though rising bond yields and currency fluctuations present near-term headwinds. Institutional interest appears strong as Japan's market rotation toward technology and AI plays supports continued ETF inflows. Key risks include BOJ policy uncertainty and global interest rate dynamics that could pressure Japanese equities.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
